Literature DB >> 4217194

Protection of mice against syngeneic lymphomata: II. Collaboration between drugs and antibodies.

D A Davies, S Buckham, A J Manstone.   

Abstract

Rabbit anti-mouse tumour cell serum can be made tumour specific by absorption with normal mouse cells and in an in vivo protection test can be shown to have a measurable protective effect on mice against a given number of lethal doses of a lymphoma. Some drugs have been evaluated in this system. When drug treatment is combined with antibody treatment much greater protection can be obtained than when the same amounts of drug or antibody are used alone. It is preferable to administer drug before antibody and with the combined schedule it is possible in the test model to protect all mice from tumour growth, even allowing the tumour up to 48 h "get-away" time before starting treatment.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4217194      PMCID: PMC2009299          DOI: 10.1038/bjc.1974.197

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  6 in total

1.  OCCURRENCE OF X ANTIGENIC SPECIFICITY IN HISTOCOMPATIBILITY ANTIGENS PREPARED FROM MOUSE LEUKAEMIC CELLS.

Authors:  D A DAVIES
Journal:  Br J Exp Pathol       Date:  1963-10

2.  MOUSE TISSUE CELL ANTIGENS. SOME PROPERTIES OF CELL-BOUND COMPONENTS.

Authors:  W BOYLE; D A DAVIES; G HAUGHTON
Journal:  Immunology       Date:  1963-09       Impact factor: 7.397

3.  Passive immunity in mice against C57BL leukosis E.L. 4 by means of iso-immune serum.

Authors:  P A GORER; D B AMOS
Journal:  Cancer Res       Date:  1956-05       Impact factor: 12.701

4.  Immunotherapy of cancer with L-phenylalanine mustard as a hapten.

Authors:  K Arai; H W Wallace; W S Blakemore
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

5.  Immunochemotherapy of cancer with chlorambucil-carrying antibody.

Authors:  T Ghose; S T Norvell; A Guclu; D Cameron; A Bodurtha; A S MacDonald
Journal:  Br Med J       Date:  1972-08-26

6.  Protection of mice against syngeneic lymphomata: I. Use of antibodies.

Authors:  D A Davies; A J Manstone; S Buckham
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

  6 in total
  6 in total

1.  Adjuvant therapy of lung cancer.

Authors: 
Journal:  Br Med J       Date:  1977-02-26

Review 2.  Oncostatic-antibody complexes in chemotherapy.

Authors:  H F Dullens; R A De Weger
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Aggregation of chlorambucil in vitro may cause misinterpretation of protein binding data.

Authors:  D Blakeslee; M Chen; J C Kennedy
Journal:  Br J Cancer       Date:  1975-06       Impact factor: 7.640

4.  Augmentation of cytotoxic drug action and X-irradiation by antibodies.

Authors:  R D Rubens; S Vaughan-Smith; R Dulbecco
Journal:  Br J Cancer       Date:  1975-09       Impact factor: 7.640

5.  Influence of C. parvum on the effectiveness of passive serotherapy in the control of the EL4 lymphoma in C57BL/6 mice.

Authors:  G J O'Neill; N Stebbing
Journal:  Br J Cancer       Date:  1980-02       Impact factor: 7.640

6.  Protection of mice against syngeneic lymphomata: I. Use of antibodies.

Authors:  D A Davies; A J Manstone; S Buckham
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.